103 related articles for article (PubMed ID: 38877209)
1. Intermittent fasting for NASH and HCC in mice.
Hindson J
Nat Rev Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38877209
[No Abstract] [Full Text] [Related]
2. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.
Gallage S; Ali A; Barragan Avila JE; Seymen N; Ramadori P; Joerke V; Zizmare L; Aicher D; Gopalsamy IK; Fong W; Kosla J; Focaccia E; Li X; Yousuf S; Sijmonsma T; Rahbari M; Kommoss KS; Billeter A; Prokosch S; Rothermel U; Mueller F; Hetzer J; Heide D; Schinkel B; Machauer T; Pichler B; Malek NP; Longerich T; Roth S; Rose AJ; Schwenck J; Trautwein C; Karimi MM; Heikenwalder M
Cell Metab; 2024 Jun; 36(6):1371-1393.e7. PubMed ID: 38718791
[TBL] [Abstract][Full Text] [Related]
3. Intermittent fasting-the future treatment in NASH patients?
Minciuna I; Gallage S; Heikenwalder M; Zelber-Sagi S; Dufour JF
Hepatology; 2023 Oct; 78(4):1290-1305. PubMed ID: 37057877
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
5. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.
Tanaka S; Miyanishi K; Kobune M; Kawano Y; Hoki T; Kubo T; Hayashi T; Sato T; Sato Y; Takimoto R; Kato J
J Gastroenterol; 2013 Nov; 48(11):1249-58. PubMed ID: 23329365
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD122 antibody restores specific CD8
Lacotte S; Slits F; Moeckli B; Peloso A; Koenig S; Tihy M; El Hajji S; Gex Q; Rubbia-Brandt L; Toso C
Oncoimmunology; 2023; 12(1):2184991. PubMed ID: 36891258
[TBL] [Abstract][Full Text] [Related]
9. miR-21-5p promotes NASH-related hepatocarcinogenesis.
Rodrigues PM; Afonso MB; Simão AL; Islam T; Gaspar MM; O'Rourke CJ; Lewinska M; Andersen JB; Arretxe E; Alonso C; Santos-Laso Á; Izquierdo-Sanchez L; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Prip-Buus C; Banales JM; Rodrigues CMP; Castro RE
Liver Int; 2023 Oct; 43(10):2256-2274. PubMed ID: 37534739
[TBL] [Abstract][Full Text] [Related]
10. Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC.
Ribas V; de la Rosa LC; Robles D; Núñez S; Segalés P; Insausti-Urkia N; Solsona-Vilarrasa E; Fernández-Checa JC; García-Ruiz C
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439245
[TBL] [Abstract][Full Text] [Related]
11. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
12.
Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
Front Immunol; 2022; 13():1047570. PubMed ID: 36531991
[TBL] [Abstract][Full Text] [Related]
13. FGF9 Recruits β-Catenin to Increase Hepatic ECM Synthesis and Promote NASH-Driven HCC.
Zhang L; Zhang Q; Teng D; Guo M; Tang K; Wang Z; Wei X; Lin L; Zhang X; Wang X; Huang D; Ren C; Yang Q; Zhang W; Gao Y; Chen W; Chang Y; Zhang H
Adv Sci (Weinh); 2023 Oct; 10(28):e2301166. PubMed ID: 37566761
[TBL] [Abstract][Full Text] [Related]
14. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
15. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
16. Lack of FGF21 promotes NASH-HCC transition
Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
[No Abstract] [Full Text] [Related]
17. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
[TBL] [Abstract][Full Text] [Related]
18. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
Boslem E; Reibe S; Carlessi R; Smeuninx B; Tegegne S; Egan CL; McLennan E; Terry LV; Nobis M; Mu A; Nowell C; Horadagoda N; Henstridge DC; Mellett NA; Timpson P; Jones M; Denisenko E; Forrest ARR; Tirnitz-Parker JEE; Meikle PJ; Rose-John S; Karin M; Febbraio MA
Sci Adv; 2023 Sep; 9(37):eadh0831. PubMed ID: 37703359
[TBL] [Abstract][Full Text] [Related]
20. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma.
Muir K; Hazim A; He Y; Peyressatre M; Kim DY; Song X; Beretta L
Cancer Res; 2013 Aug; 73(15):4722-31. PubMed ID: 23749645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
